Non-small Cell Lung Cancer
Conditions
Brief summary
The purpose of this study is to study the effect of hormone therapies (androgen pathway modification) on the outcomes of patients with lung cancer. This information may be of benefit for future treatment strategies, prevention and control. In this study, the protein where testosterone binds, called the androgen receptor (AR), will be measured in samples from the patient's biopsy and surgical tumor samples. The investigators will look at a marker of how fast the cancer is growing (Ki67) before using finasteride from your biopsy specimen. Finasteride will be taken from the day of consent until the day of the patient's surgery. This marker will be measured again after using finasteride from the surgical specimen. The investigators will be looking for a decrease in the Ki67 from the patient's biopsy specimen to the surgical specimen as an indicator that this medication is blocking tumour growth.
Interventions
DRUGfinasteride 5mg oral daily
Sponsors
CancerCare Manitoba
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* male * age \>18 * biopsy-proven non-small cell lung cancer * surgical intervention planned
Exclusion criteria
* current use of 5-alpha reductase inhibitor * previous diagnosis of prostate cancer * previous hypersensitivity to 5-alpha reductase inhibitor
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in proliferation | Original biopsy to surgical specimen (approx 6 weeks) | Patients will be followed from time of consent (around the time of consultation with a Thoracic Surgeon) to date of surgery (on average, approximately 4-6 weeks following Thoracic Surgeon consultation). |
Countries
Canada
Outcome results
None listed